 BioVie Inc NASDAQ:BIVI said it has made significant progress with its clinical programs, including its drug candidate NE3107 showing a clinically meaningful increase in motor control in patients with Parkinsons disease who were treated with the drug for 28 days. In a letter to shareholders, BioVie CEO Cuong Do said over the course of 2022, the company provided positive topline results from its Alzheimers Disease AD and Parkinsons Disease PD trials. 